2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B1513
    α-Cyclodextrin
    		Inhibitor 99.96%
    α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against SARS-CoV-2 infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids.
    α-Cyclodextrin
  • HY-N0539
    Calceolarioside B
    		Inhibitor 99.93%
    Calceolarioside B is a phenylethanoid glycoside. Calceolarioside B can be isolated from the leaves of Akebia quinata. Calceolarioside B inhibits RLAR activity with an IC50 value of 23.99 μM. Calceolarioside B inhibits the entry of Omicron BA.2 into host cells. Calceolarioside B reduces IL-6 levels. Calceolarioside B has immunomodulatory activity. Calceolarioside B has anticancer activity against human hormone-independent prostate cancer.
    Calceolarioside B
  • HY-17430
    Amprenavir
    		Inhibitor 99.55%
    Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
    Amprenavir
  • HY-117626
    LP-935509
    		Inhibitor 99.74%
    LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research.
    LP-935509
  • HY-N2183
    Baimaside
    		Inhibitor 99.57%
    Baimaside (Quercetin 3-O-sophoroside) is a flavonoid cholinergic function modulator that binds to SARS-CoV-2-related targets. Baimaside regulates the expression of cholinergic system-related proteins and acetylcholine levels, improves scopolamine-induced learning and memory impairment, protects hippocampal neurons, inhibits pollen protein fluorescence, and protects pollen DNA. Its biosynthesis is regulated by multiple enzymes. Baimaside is completely absorbed in rats, undergoes phase Ⅱ metabolism and gut microbiota decomposition, and inhibits the invasion and proliferation of SARS-CoV-2 and its variants, making it suitable for research related to Alzheimer's disease and COVID-19.
    Baimaside
  • HY-N3415
    Kumatakenin
    		Inhibitor 99.31%
    Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor, with a Kd value of 2.94 μM for mouse ATG5. Kumatakenin increases the activities of caspase-3, caspase-8 and caspase-9, thereby inducing caspase-dependent apoptosis in ovarian cancer cells. Kumatakenin reduces the expression of chemokines and pro-oncogenic factors in ovarian cancer cells, and inhibits M2 macrophage polarization. Kumatakenin inactivates TRIM65 function, reduces the expression and stability of FASN, and thus inhibits the proliferation, migration, invasion and tumor progression of esophageal cancer cells. Kumatakenin interacts with ATG5 to reduce its protein level, decrease LC3 level, and reduce the number of autophagosomes in the hippocampus. Kumatakenin binds to Eno3 to upregulate its expression, reduce the stability and expression level of IRP1 mRNA, inhibit ferroptosis, alleviate intestinal inflammation, and restore epithelial barrier function. Kumatakenin enhances the efficacy of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production. Kumatakenin is applicable to research related to ovarian cancer, esophageal cancer, depression and colitis.
    Kumatakenin
  • HY-W012531
    2-Hydroxycinnamic acid
    		Inhibitor 99.86%
    2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC50 of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity.
    2-Hydroxycinnamic acid
  • HY-131611
    6-Azuridine
    		Inhibitor 99.83%
    6-Azuridine (6-Azauridine) is an orally active purine nucleoside analogue. 6-Azuridine activates autophagic flux, induces Apoptosis that depends on AMPK and p53. 6-Azuridine exhibit both antitumor and antiviral activities.
    6-Azuridine
  • HY-N1951
    Miltirone
    		Inhibitor 99.54%
    Miltirone is an orally active natural compound found in the root of Salvia miltiorrhiza. Miltirone is a central benzodiazepine receptor partial agonist, with an IC50 of 0.3 μM. Miltirone induces ROS - and-p53 dependent apoptosis. Miltirone inhibits carboxylesterase 2 (CES2; Ki = 0.04 μM) and SARS-CoV main protease (Mpro).
    Miltirone
  • HY-10237
    Boceprevir
    		Inhibitor 98.52%
    Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 3CLpro activity.
    Boceprevir
  • HY-17367A
    Atazanavir sulfate
    		Inhibitor 99.68%
    Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor with blood-brain barrier permeability. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
    Atazanavir sulfate
  • HY-P99344
    Bamlanivimab
    		Inhibitor 99.97%
    Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab.
    Bamlanivimab
  • HY-P99556
    Tixagevimab
    		Inhibitor 99.05%
    Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
    Tixagevimab
  • HY-B1400
    Diiodohydroxyquinoline
    		Inhibitor 98.0%
    Diiodohydroxyquinoline (Iodoquinol, 5,7-Diiodo-8-hydroxyquinoline, 5,7-Diiodo-8-quinolinol) has an orally active and satisfactory antiparasitic properties. Diiodohydroxyquinoline exhibits mutagenic potential in mice and potent anti-SARS-CoV-2 activity with an EC50 value of 1.38 μM in VeroE6 cells. Diiodohydroxyquinoline's antimutagen is ascorbic acid. Diiodohydroxyquinoline is promising for research in inflammationin, testinal amebiasis, amebic liver abscess and chronic nonspecific diarrheas.
    Diiodohydroxyquinoline
  • HY-N2116
    Ginkgolic acid C17:1
    		Inhibitor 99.80%
    Ginkgolic acid C17:1 is a fatty acid synthase (FAS) inhibitor with an IC50 of 10.5 µM. Ginkgolic acid C17:1 shows anti-tumor activity by inhibiting the phosphorylation of STAT3 and inducing apoptosis. Ginkgolic acid C17:1 can block the interaction between S-RBD and ACE2, and has anti-SARS-CoV-2-S pseudovirus activity. Ginkgolic acid C17:1 inhibits the biofilm formation of enterohemorrhagic Escherichia coli and Staphylococcus aureus.
    Ginkgolic acid C17:1
  • HY-11007
    GNF-2
    		Inhibitor 99.82%
    GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC50 of 138 nM .
    GNF-2
  • HY-117813
    2-Thiouridine
    		Inhibitor 99.92%
    2-Thiouridine is an orally active modified nucleobase. 2-Thiouridine stabilizes U:A base pairs and destabilizes U:G wobble base pairs. 2-Thiouridine significantly improves the efficiency and accuracy of nonenzymatic replication of mixed-sequence A/U-containing RNA templates. 2-Thiouridine exhibits antiviral activity against multiple positive-sense single-stranded RNA viruses (DENV2, ZIKV, YFV, JEV, WNV, CHIKV, human coronaviruses ( [HCoV]-229E, HCoV-OC43, SARS-CoV), and MERS-CoV).
    2-Thiouridine
  • HY-137958A
    Bemnifosbuvir
    		Inhibitor 99.00%
    Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity.
    Bemnifosbuvir
  • HY-P99520
    Vilobelimab
    		99.27%
    Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc.
    Vilobelimab
  • HY-P99341
    Casirivimab
    		Inhibitor 99.54%
    Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms.
    Casirivimab
Cat. No. Product Name / Synonyms Species Source